term
amount
matern
igg
antibodi
higher
neonat
mother
pattern
hold
igg
antibodi
medic
specif
fc
receptor
neonat
fcrn
facilit
transfer
igg
antibodi
across
syncytiotrophoblast
fetal
circul
kane
acquah
due
high
rate
igg
transfer
near
term
babi
found
similar
blood
level
infliximab
mother
discontinu
drug
week
prior
deliveri
babi
like
born
minim
serum
level
thu
avoid
immunosuppress
young
infant
though
suggest
data
certolizumab
cross
placenta
easili
igg
deriv
drug
due
pegyl
molecul
clows
earli
human
placenta
exchang
tissu
area
villi
form
around
entir
surfac
conceptu
placent
shape
call
diffus
placenta
third
month
pregnanc
villi
near
initi
site
implant
persist
lead
format
discshap
placenta
although
chorioallanto
placenta
human
begin
function
alreadi
end
fourth
week
pregnanc
process
complet
format
diskshap
placenta
sadler
first
trimest
human
fetu
surround
two
fluid
caviti
ie
inner
amniot
caviti
outer
extraembryon
coelom
caviti
chorioallanto
placenta
form
fetal
vessel
endothelium
trophoblast
layer
bath
directli
matern
blood
van
der
aa
et
al
monoclon
therapeut
compound
toxic
studi
broad
sens
perform
signific
matern
fetal
neonat
toxic
observ
remain
seven
product
common
advers
effect
reproduct
develop
reduc
fetal
weight
increas
abort
rate
reduct
fertil
indic
gener
toxic
compound
pentsuk
van
der
laan
twentyfour
children
one
congenit
anomali
part
vacterl
associ
one
child
matern
etanercept
administr
diagnos
vacterl
associ
ie
v
vertebr
defect
anal
atresia
imperfor
anu
c
cardiac
abnorm
atrial
septal
defect
ventricular
septal
defect
tetralog
fallot
tracheoesophag
fistula
tracheal
atresiastenosi
e
esophag
atresia
r
radial
renal
abnorm
preaxial
l
limb
abnorm
carter
et
al
interact
play
critic
role
biolog
function
antibodi
like
instrument
prevent
modul
lentivir
infect
antibodi
respons
depend
interact
may
help
widen
spectrum
increas
potenc
vaccineinduc
antibodi
forthal
moog
maternofet
transmiss
nonneutralis
dengu
viru
specif
antibodi
result
develop
hemorrhag
fever
newborn
even
case
first
infect
heterotyp
viru
mechan
format
nonneutralis
neonat
viru
heterotyp
matern
igg
complex
taken
endotheli
hematopoet
cell
virusabfc
pinocytosi
risk
disappear
month
age
children
matern
igg
disappear
circul
children
librati
et
al
phenomenon
observ
case
flavivirus
enterovirus
ferenczi
et
al
wang
et
al
dengu
serotyp
crossreact
cytotox
lymphocyt
ctl
clone
show
high
avid
antigen
produc
higher
level
inflammatori
cytokin
serotypespecif
clone
high
avid
crossreact
memori
ctl
may
produc
inflammatori
cytokin
cours
secondari
infect
contribut
pathogenesi
vascular
leak
cell
appear
subsequ
delet
leav
serotypespecif
memori
ctl
pool
antibodydepend
enhanc
ade
neither
suffici
absolut
necessari
precondit
develop
sever
shock
syndrom
hemorrhag
diseas
ctl
respons
viral
infect
modul
infect
histori
individu
manner
like
contribut
diseas
sever
dong
et
al
et
al
respiratori
syncyti
viru
rsv
enhanc
activ
transplacent
matern
antibodi
observ
first
osiowi
et
al
rsv
infect
also
enhanc
nonneutralis
antibodi
johnson
graham
vaccin
use
inactiv
viru
particl
caus
immun
enhanc
case
rsv
contrast
exampl
influenza
virus
openshaw
et
al
ye
et
al
cytotox
tcell
cytokin
interferon
induct
tolllik
receptor
may
potenti
enhanc
mobb
et
al
boukhvalova
et
al
tregon
et
al
lee
et
al
b
nguyen
et
al
ubol
halstead
tumour
necrosi
factor
block
cellrepl
enhanc
rsvreplic
gibb
et
al
evid
enhanc
effect
nonneutr
antibodi
rsv
prevent
treatment
children
increas
risk
neutral
monoclon
antibodi
direct
fusion
f
protein
rsv
motavizumab
andor
palivizumab
monoclon
antibodi
found
caus
harm
effect
connect
prevent
treatment
neonat
infant
risk
martinmateo
nieri
et
al
weisman
groothui
et
al
antirsvf
protein
specif
antibodi
prevent
also
rsv
pneumonia
enhanc
respiratori
infect
hament
et
al
block
influenza
specif
antineuraminidas
antibodi
use
antiidiotyp
indirectli
enhanc
hemagglutinationinhibit
titer
antisera
dowdl
et
al
influenza
specif
antisera
found
enhanc
viru
replic
macrophagelik
cell
line
cell
previous
treat
neuraminidas
remov
viral
receptor
ochiai
et
al
system
lupu
erythemadosu
sle
characteris
antibodi
toward
dsdna
ligas
regul
tlr
signal
present
sever
year
onset
diseas
neonat
diseas
caus
transplacent
antibodi
watson
et
al
system
lupu
erythematosu
sle
common
autoimmun
diseas
affect
women
reproduct
age
associ
poor
matern
fetal
outcom
treg
cell
subset
lymphocyt
potent
immunosuppress
activ
play
crucial
role
control
immunolog
self
toler
evid
suggest
augment
pregnanc
especi
first
trimest
suggest
import
role
earli
placent
develop
literatur
describ
treg
cell
sle
conflict
sle
associ
reduc
number
function
defect
treg
cell
may
predispos
pregnant
women
diseas
pregnanc
complic
articl
discuss
role
treg
cell
sle
pregnanc
cell
may
contribut
poor
pregnanc
outcom
sleaffect
women
bloi
et
al
clark
et
al
sle
induc
interferon
administr
specif
stimuli
ie
sunshin
exposur
smoke
haplotyp
also
found
risk
factor
klareskog
et
al
alcohol
consumpt
shown
protect
ill
vaccin
adult
age
found
innocu
concern
risk
ra
accord
result
studi
common
vaccin
year
onset
ra
follow
effect
environ
howev
unknown
neonat
heart
block
posit
women
activ
immunis
increas
risk
bengtsson
et
al
b
sle
diseas
pregnant
high
antibodi
titer
epitop
almost
exclus
carri
risk
fetus
develop
neonat
heart
block
gestat
week
monitor
period
antibodi
steroid
treatment
prevent
utero
pacemak
treatment
may
reduc
risk
wahrenherleniu
foetal
gene
matern
age
infecti
agent
may
contribut
risk
congenit
heart
block
especi
inherit
high
level
interferon
product
also
shown
risk
factor
sle
niewold
et
al
heparin
treatment
intraven
gamma
globulin
ivig
treatment
specif
antiidiotyp
reduc
risk
diseas
clark
et
al
ivig
enhanc
antiid
antibodi
respons
pregnant
women
antilassb
antibodi
id
antiid
ratio
significantli
higher
mother
whose
offspr
develop
neonat
lupu
compar
mother
gave
birth
healthi
child
p
remov
antiid
antibodi
substanti
increas
reactiv
la
sera
five
seven
mother
test
ivig
batch
administ
mother
gave
birth
healthi
child
id
antiid
activ
ratio
contrast
given
mother
gave
birth
child
neonat
lupu
brucato
et
al
routsia
et
al
main
pathomechan
develop
neonat
lupu
erythematosu
transcytosi
matern
antibodi
probabl
microchimer
cell
pathogenesi
matern
diseas
extrem
complex
summaris
recent
perl
perl
et
al
mitochondri
hyperpolar
underli
mitochondri
dysfunct
deplet
atp
oxid
stress
abnorm
activ
death
signal
process
lupu
cell
nitric
oxid
product
express
endogen
retrovir
repetit
element
long
interspers
nuclear
element
interferon
alpha
ifnalpha
tolllik
receptor
highmobl
group
protein
extracellular
signalregul
kinas
dna
methyl
transferas
histon
deacetylas
spleen
tyrosin
kinas
proteasom
function
lysosom
function
endosom
recycl
actin
cytoskeleton
format
nuclear
factor
kappa
b
pathway
activ
cytotox
cell
shown
compon
pathogenesi
varghes
et
al
human
endogen
retroviru
erv
encod
nuclear
autoantigen
small
gtpase
term
target
crossreact
antivir
antibodi
wherea
regul
surfac
express
via
endosom
recycl
overexpress
lupu
cell
correl
increas
recycl
contribut
downregul
via
lysosom
degrad
erv
protein
may
trigger
lupu
structur
function
molecular
mimicri
wherea
accumul
ervderiv
nucleic
acid
stimul
interferon
antidna
antibodi
product
erv
protein
may
trigger
lupu
structur
function
molecular
mimicri
wherea
accumul
ervderiv
nucleic
acid
stimul
interferon
antidna
antibodi
product
sle
perl
perl
et
al
complex
pathogenet
factor
mani
influenc
pregnanc
result
clinic
diseas
newborn
ruizirastorza
khamashta
neonat
lupu
erythematosu
nle
inflammatori
disord
neonat
character
transient
cutan
lesion
andor
congenit
heart
block
cutan
lesion
usual
heal
minim
scar
within
month
may
delay
mani
month
occasion
case
matern
antibodi
disappear
circul
newborn
within
month
longlast
clinic
symptom
indic
irrevers
event
impair
fetal
cell
occur
fetal
life
photosensit
recogn
compon
syndrom
specif
antibodi
detect
circul
newborn
skin
cardiac
manifest
coexist
patient
hepat
hematolog
less
commonli
pulmonari
neurolog
gastrointestin
abnorm
may
also
present
watson
et
al
perez
et
al
neonat
lupu
model
passiv
acquir
autoimmun
mother
may
system
lupu
erythematosu
sle
syndrom
ss
may
entir
asymptomaticsynthes
antibodi
ssaro
andor
ssbla
ribonucleoprotein
enter
fetal
circul
via
trophoblast
fcrn
receptor
presum
caus
tissu
injuri
lee
mention
congenit
heart
block
passiv
transfer
autoimmun
condit
affect
children
mother
rossa
autoantibodi
pregnanc
antibodi
transport
across
placenta
affect
fetu
previous
demonstr
antibodi
direct
amino
acid
aa
stretch
compon
rossa
antigen
correl
develop
congenit
heart
block
antibodi
recognit
depend
partli
alphahel
fold
within
put
leucin
zipper
aa
stretch
ottosson
et
al
smith
sm
antigen
highli
specif
sle
compos
least
nine
differ
polypeptid
molecular
weight
rang
kda
b
kda
kda
n
kda
kda
kda
kda
e
kda
f
kda
g
kda
sle
patient
develop
antibodi
sm
complex
small
nuclear
rna
mother
recent
also
detect
neonat
le
patient
ortizsantamaria
et
al
neonat
lupu
mother
high
antiidiotyp
antibodi
activ
antila
autoantibodi
lower
risk
give
birth
unhealthi
child
compar
mother
without
antiidiotyp
antibodi
usual
antiidiotyp
antibodi
may
confer
protect
harm
effect
autoantibodi
certain
autoimmun
diseas
tzioufa
routsia
ivig
enhanc
antiid
antibodi
respons
pregnant
women
antilassb
antibodi
high
id
antiid
ratio
ivig
prepar
matern
serum
may
explain
absenc
effect
ivig
prevent
recurr
neonat
lupu
case
routsia
et
al
children
mother
suffer
sle
syndrom
risk
also
rheumaticautoimmun
diseas
without
carri
antibodi
reactiv
ssaro
ssbla
antigen
among
sibl
without
neonat
lupu
develop
later
juvenil
rheumatoid
arthriti
hashimoto
thyroid
psoriasi
iriti
diabet
mellitu
congenit
hypothyroid
nephrot
syndrom
martin
et
al
winter
schatz
experiment
system
lupu
erythemetosu
could
induc
mice
use
immunis
antiidiotyp
antibodi
specif
antidnaspecif
monoclon
antibodi
mendlov
et
al
ident
twin
mother
suffer
sle
also
transient
neonat
bullou
skin
diseas
nakajima
et
al
autoimmun
defin
normal
physiolog
state
control
mechan
prevent
autoimmun
progress
overt
patholog
onset
subset
rheumatoid
arthriti
ra
begin
appear
citrullin
protein
antigen
cpa
posit
toler
certain
citrullin
proteinspeptid
broken
support
certain
hladr
haplotyp
smoker
local
express
peptidylarginin
deiminas
occasion
elev
inflammatori
cytokin
measur
klareskog
et
al
methotrex
significantli
effect
placebo
prevent
progress
diseas
state
anticpaposit
patient
undifferenti
arthriti
ua
wherea
differ
methotrex
placebo
seen
acpaneg
group
patient
undifferenti
arthriti
ua
arthriti
without
arthralgia
risk
ra
lower
group
without
treatment
ehrenstein
et
al
van
dongen
et
al
treatment
use
therapi
infliximab
tumour
necrosi
factor
blocker
abatacept
cell
costimul
inhibitor
result
signific
improv
acpa
patient
ua
saleem
et
al
emeri
et
al
analysi
myeloidrel
protein
serum
excel
tool
diagnosi
system
onset
juvenil
idiopath
arthriti
jia
allow
earli
differenti
patient
systemiconset
jia
inflammatori
diseas
repres
novel
posit
feedback
mechan
activ
phagocyt
via
two
major
signal
pathway
innat
immun
pathogenesi
systemiconset
jia
frosch
et
al
rheumatoid
arthriti
found
improv
pregnanc
probabl
due
galactosyl
igg
molecul
women
ra
acquir
suscept
allel
microchimer
cell
high
amount
total
pbmc
microchimer
patient
ra
observ
similarli
microchimer
dna
observ
significantli
higher
quantiti
women
ra
compar
healthi
control
subject
contrast
differ
women
ra
control
subject
microchimer
allel
analyz
rak
et
al
analog
graftversushost
diseas
gvhd
pioneer
studi
microchimer
women
scleroderma
propos
direct
indirect
recognit
mechan
underli
reaction
microchimer
cell
nelson
gvhd
donor
cell
invad
recipi
observ
microchimer
patient
ra
howev
presenc
microchimer
microchimer
neglig
frequenc
among
total
host
pbmc
similar
frequenc
antigenspecif
cell
thu
suffici
impact
host
immun
reaction
haplotyp
patient
influenc
progress
rheumatoid
arthriti
liu
et
al
autoimmun
neonat
bullou
skin
diseas
caus
placent
transfer
matern
igg
autoantibodi
rare
report
neonat
born
mother
pemphigu
vulgari
pemphigu
foliaceu
gestat
pemphigoid
vertic
acquir
congenit
autoimmun
blister
disord
appear
selflimit
resolv
support
therapi
concomit
presum
clearanc
matern
autoantibodi
neonat
circul
abram
et
al
antiphospholipid
antibodi
syndrom
apa
regard
frequent
acquir
risk
factor
thrombophilia
thrombophilia
tendenc
thrombosi
antiphospholipid
antibodi
syndrom
apa
disord
recurr
vascular
thrombosi
pregnanc
loss
thrombocytopenia
associ
persist
rais
level
antiphospholipid
antibodi
apa
apa
phospholipid
part
cell
membran
recogn
bodi
foreign
antibodi
produc
matern
autoimmun
diseas
significantli
reduc
pregnanc
outcom
women
frequent
ill
antiphospholipid
syndrom
antiphospholipid
syndrom
associ
rheumat
diseas
apsrd
rd
patient
isol
autoantibodi
autoab
absenc
definit
autoimmun
diseas
aab
reactiv
arthriti
spondyloarthropathi
patient
previou
pregnanc
complic
anamnest
livebirth
rate
patient
pregnanc
result
preterm
deliveri
newborn
low
weight
deliveri
apsrd
patient
wors
outcom
result
miscarriag
result
growth
restrict
result
preterm
deliveri
result
mainli
due
patient
apssystem
lupu
erythematosu
sle
lowest
gestat
age
deliveri
week
lowest
newborn
weight
canti
et
antiphospholipid
syndrom
suggest
result
antibodi
direct
cardiolipin
result
antigen
mimicri
suspect
antigen
sherer
et
al
clinic
signific
lupu
anticoagul
anticardiolipin
antibodi
glycoproteini
gpi
antibodi
neonat
born
mother
primari
ap
risk
prematur
small
gestat
age
thrombocytopenia
chou
et
al
antiphospholipid
antibodi
apl
impair
physiolog
develop
fetu
pregnanc
caus
thrombosi
placent
vessel
also
directli
bind
throphoblast
cell
modifi
function
tincani
et
al
transplacent
transfer
antiphospholipid
antibodi
act
risk
factor
usual
suffici
condit
thrombosi
thrombophil
risk
factor
systemat
evalu
longterm
studi
children
born
antiphospholipidantibodyposit
mother
provid
evid
possibl
neurodevelopment
chang
children
regular
neuropsycholog
assess
recommend
antiphospholipidantibodyrel
thrombos
children
frequent
associ
multipl
antiphospholipid
antibodi
posit
concomit
presenc
inherit
prothrombot
disord
also
detect
addit
nonthrombot
manifest
particularli
hematolog
skin
neurolog
manifest
avcin
treatment
pregnant
women
apa
result
mark
improv
live
birth
rate
howev
complic
like
preeclampsia
intrauterin
growth
restrict
iugr
occur
even
treatment
requir
strict
monitor
time
deliveri
aberr
concentr
fetuin
heat
shock
protein
might
also
role
preeclampt
inflamm
molvarec
et
al
b
dadhwal
et
al
foetalneonat
diseas
due
transplacent
thyrotrophin
receptor
stimul
antibodi
trab
extrem
import
recognis
treat
grave
diseas
mother
soon
possibl
thyrotox
state
may
advers
effect
outcom
pregnanc
foetu
newborn
neonat
grave
diseas
tend
resolv
spontan
within
week
matern
thyroid
stimul
immunoglobulin
clear
circul
subsequ
develop
may
impair
perceptu
motor
difficulti
hashimoto
thyroid
common
autoimmun
thyroid
diseas
presenc
matern
hashimoto
thyroid
usual
consequ
foetal
thyroid
even
antitpo
antitg
antibodi
found
newborn
due
transplacent
passag
howev
report
describ
foetal
neonat
hyperthyroid
affect
mother
offspr
radetti
et
al
hemminki
et
al
number
autoimmun
diseas
especi
autoimmun
thyroid
diseas
erythema
nodosum
sarcoidosi
pariti
might
somehow
involv
matern
diseas
develop
et
al
matern
thyroid
statu
assess
treatment
improv
fetal
outcom
neuropsycholog
development
newborn
staii
et
al
juvenil
myasthenia
gravi
associ
antibodi
acetylcholin
receptor
achr
patient
thymoma
rare
often
malign
children
frequenc
juvenil
myasthenia
gravi
antibodi
musclespecif
kinas
musk
vari
markedli
differ
countri
neonat
myasthenia
gravi
associ
musk
antibodi
often
sever
protract
albeit
transient
diseas
et
al
evoli
transient
neonat
myasthenia
gravi
mg
human
model
passiv
transfer
diseas
although
newborn
babi
myasthen
mother
antiachr
antibodi
birth
morel
et
al
tzarto
et
al
small
percentag
express
myasthen
syndrom
namba
et
al
myasthen
symptom
usual
appear
hour
birth
averag
durat
week
neonat
myasthenia
gravi
transient
transfer
mother
newborn
nicotin
acetylcholin
receptor
achr
antibodi
result
loss
achr
also
directli
block
function
remain
achr
molecul
therebi
caus
defect
neuromuscular
transmiss
major
though
myasthen
nonmyasthen
infant
found
repertoir
antiachr
specif
similar
mother
signific
differ
observ
sera
two
group
mother
adequ
treatment
mother
reduc
frequenc
sever
neonat
diseas
neonat
diseas
recov
follow
ivig
treatment
et
al
carrol
et
al
absenc
neonat
myasthenia
gravi
might
caus
antigen
differ
fetal
adult
enzym
similar
detect
rat
hall
et
al
hesselman
et
al
human
fetal
acetylcholin
receptor
achr
present
week
gestat
fetal
subunit
replac
adult
subunit
term
fetal
acetylcholin
receptor
inactiv
syndrom
propos
ill
development
disord
also
caus
matern
antibodi
oskoui
et
al
neonat
syndrom
gb
observ
occur
day
postpartum
children
born
mother
gb
serum
mother
infant
depress
quantal
content
approxim
reduc
amplitud
postsynapt
current
mous
newborn
juvenil
rat
antibodi
natur
blockad
could
confirm
show
monoval
fab
fragment
similarli
effect
purifi
immunoglobulin
ig
g
cellular
humor
immun
mechan
oper
syndrom
gb
transplacent
transfer
block
antibodi
may
specif
direct
epitop
matur
fetal
neuromuscular
junction
luijckx
et
al
buchwald
et
al
syndrom
sydenheim
chorea
diseas
shown
associ
immun
respons
microbi
infect
occurr
syndrom
note
infant
whose
mother
harmless
autoimmun
antibodi
pregnanc
buchwald
et
al
sladki
syndrom
occurr
within
famili
also
interest
c
tnfa
c
snp
associ
sever
weak
poor
outcom
indic
snp
may
one
factor
predispos
sever
form
gb
geleijn
et
al
associ
featur
carrier
consist
favor
metabol
bodi
composit
condit
contrast
polymorph
report
associ
enhanc
sensit
glycocorticoid
haplotyp
carri
minor
allel
bcli
polymorph
glycocorticoid
receptor
gene
relat
phenotyp
outcom
gb
explain
famili
depend
syndrom
neonat
disord
dekker
et
al
mutat
dozen
gene
link
develop
perman
neonat
diabet
mellitu
pndm
frequent
caus
pndm
heterozyg
mutat
in
gene
although
pndm
rare
phenomenon
one
case
live
birth
discoveri
larg
impact
clinic
practic
carrier
gene
mutat
switch
insulin
oral
sulphonylurea
improv
glycem
control
aguilarbryan
bryan
rubiocabeza
et
al
major
transient
neonat
diabet
mellitu
tndm
case
abnorm
chromosom
half
ndm
case
transient
tndm
frequent
caus
ndm
missens
mutat
pancreat
katp
channel
gene
in
preproinsulin
gene
ndm
link
numer
genet
caus
includ
point
mutat
gck
chrx
aguilarbryan
bryan
bonnefond
et
al
genet
mutat
identifi
nonconsanguin
proband
pndmmdi
use
sequenti
screen
in
gene
infant
diagnos
within
first
month
age
percentag
decreas
diabet
diagnos
month
patient
belong
latter
group
may
either
carri
mutat
gene
differ
commonli
found
pndmmdi
develop
earlyonset
form
autoimmun
diabet
isletcel
antibodi
ica
glutam
acid
decarboxylas
autoantibodi
gada
tyrosin
phosphataserel
proteinsislet
antigen
autoantibodi
insulin
autoantibodi
iaa
zinc
transport
autoantibodi
found
sera
children
suggest
autoimmun
origin
diseas
russo
et
al
biliari
atresia
ba
devast
diseas
infant
invari
lead
cirrhosi
endstag
liver
diseas
death
untreat
shown
use
microarray
techniqu
tcell
regulatori
gene
rra
seem
key
factor
develop
diseas
zhao
et
al
recent
review
report
ba
may
involv
primari
perinat
hepatobiliari
reovir
rotavir
infect
secondari
autoimmunemedi
bile
duct
injuri
mack
matern
viru
infect
follow
maternofoet
microchimer
seem
impress
explan
etiolog
muraji
et
al
mous
model
oral
vaccin
mate
rotateq
rotarix
prevent
rhesu
rotavirusinduc
ba
turowski
et
al
biliari
atresia
probabl
endresult
differ
aetiolog
factor
among
virus
agent
may
cross
placenta
otherwis
understand
one
twin
obtain
diseas
morri
et
al
antiidiotyp
transcytos
differ
effici
circul
twin
might
addit
explan
asymmetr
diseas
matern
symptomless
paraproteinemia
also
found
transmit
fetu
paraprotein
detect
birth
month
serum
child
caus
prolong
immunosuppress
without
later
consequ
littlewood
et
al
littlewood
payn
transient
neonat
acquir
von
willebrand
syndrom
avw
observ
peripartum
clinic
manag
analog
monoclon
gammopathi
undetermin
signific
mgu
mother
sinc
consequ
transplacent
transfer
matern
igg
antibodi
simon
et
al
nageswara
rao
et
al
immun
trombocytopen
purpura
associ
pregnanc
fetal
neonat
alloimmun
thromocytopenia
fmait
result
transplacent
transfer
matern
antibodi
develop
respons
alloimmun
patern
human
platelet
antigen
hpa
express
fetal
platelet
thrombocyt
loss
could
prevent
use
modifi
igg
molecul
ghevaert
et
al
present
seven
biallel
human
platelet
antigen
hpa
system
determin
type
use
genom
dna
platelet
genotyp
valuabl
tool
confirm
platelet
antigen
specif
alloantibodi
detect
patient
sera
complement
clinic
histori
diagnosi
alloimmun
platelet
disord
fetal
neonat
alloimmun
thrombocytopenia
fnait
prenat
platelet
type
fetu
suspect
case
fnait
becam
also
avail
curti
half
infant
born
low
platelet
count
requir
replac
therapi
upon
birth
ozkan
et
al
gasim
matern
transplacent
igg
bind
fetal
platelet
suggest
prevent
recircul
bind
phagocytosi
macrophag
pathogenesi
immun
trompcytopen
purpura
associ
myelodysplasia
leukemia
shown
differ
psaila
bussel
psaila
et
al
neonat
endarter
diagnos
newborn
mother
suffer
endarter
nodosa
fatal
myocardi
infarct
neonat
due
coronari
arteri
compar
two
lethal
case
mucocutan
lymph
node
syndrom
andor
infantil
periarter
nodosa
mlnsipn
cutan
polyarter
transmit
newborn
kitzmil
krapf
et
al
stone
et
al
last
decad
public
could
found
neonat
endarter
probabl
pathogenesi
diseas
reevalu
light
molecular
diagnost
find
hereditari
autoinflammatori
syndrom
caus
monogen
defect
innat
immun
classifi
primari
immunodefici
syndrom
character
recurr
persist
system
inflammatori
symptom
must
distinguish
infecti
diseas
autoimmun
diseas
primari
immunodefici
site
review
describ
epidemiolog
clinic
laboratori
featur
prognosi
treatment
main
autoinflammatori
syndrom
name
famili
mediterranean
fever
tnf
receptor
associ
period
syndrom
cryopyrinopathi
mevalon
kinas
defici
pediatr
granulomat
arthriti
pyogen
arthriti
pyoderma
gangrenosum
acn
syndrom
maje
syndrom
defici
interleukin
receptor
antagonist
cryopyrinopathi
discuss
includ
neonatalonset
multisystem
inflammatori
diseas
also
known
chronic
infantil
neurolog
cutan
articular
syndrom
mucklewel
syndrom
famili
cold
autoinflammatori
syndrom
jesu
et
al
primari
immunodefici
pid
analyz
gain
insight
physiopatholog
sle
pid
consist
associ
sle
lupuslik
manifest
homozyg
defici
earli
compon
classic
complement
pathway
follow
decreas
order
affect
patient
develop
sle
b
femal
carrier
xlink
chronic
granulomat
diseas
allel
c
iga
defici
present
around
juvenil
sle
mutat
complement
system
defici
shown
facilit
develop
sle
addit
facilit
bacteri
infect
encapsul
bacteria
neisseria
autoimmun
diseas
ie
polyendocrinopathi
candidiasi
ectoderm
dystrophi
apec
immun
dysregul
polyendocrinopathi
enteropathi
xlink
ipex
autoimmun
lymphoprolif
syndrom
alp
suggest
mechan
consid
critic
player
induct
mainten
toler
autoantigen
airemedi
thymic
neg
select
lymphocyt
regulatori
cell
mediat
peripher
toler
delet
autoreact
lymphocyt
fasmedi
apoptosi
found
associ
sle
physiopatholog
bloi
et
al
carneirosampaio
et
al
syndrom
bs
multisystem
chronic
inflammatori
disord
character
relaps
oral
genit
ulcer
iridocycl
unknown
etiolog
vasculit
chang
possibl
autoimmun
origin
common
involv
organ
thrombot
complic
may
advers
affect
gestat
frequent
seen
shown
possess
genet
etiolog
basi
comparison
incid
among
monozygot
dizygot
twin
masatlioglu
et
al
pregnanc
deleteri
effect
cours
bd
may
possibl
amelior
cours
howev
seem
bd
may
advers
affect
pregnanc
miscarriag
rate
higher
pregnanc
complic
cesarean
section
rate
significantli
elev
jadaon
et
al
overal
pariti
associ
increas
risk
femal
predomin
autoimmun
diseas
pregnanc
result
liveborn
children
therefor
seem
contribut
littl
gener
femal
predomin
autoimmun
diseas
crohn
diseas
ulcer
coliti
idiopath
inflammatori
bowel
diseas
ibd
includ
crohn
diseas
ulcer
coliti
pathogen
buildup
cell
site
inflamm
mediat
part
provid
describ
earlier
antiapoptot
signal
cell
induct
bclxl
promot
lineag
differenti
upregul
patient
type
ibd
level
elev
markedli
serum
patient
ibd
decreas
treatment
inflamm
predict
ibd
relaps
microbi
patternrecognit
receptor
tlr
nucleotid
oligomer
domain
activ
nfkb
implic
condit
neutralis
antibodi
larg
prevent
coliti
mice
arad
et
al
women
men
ulcer
coliti
uc
crohn
diseas
cd
expect
healthi
child
neither
preterm
birth
low
birthweight
neonat
form
describ
ludvigsson
ludvigsson
van
assch
et
al
later
crohn
diseas
shown
impair
fetal
outcom
case
affect
mother
naganuma
et
al
colitisassociatedcanc
cac
suppress
format
cancer
inhibit
transsign
human
sampl
colon
cancer
lowlevel
sampl
inflam
colon
adenomat
polyposi
coli
apc
gene
mice
apc
mutat
develop
cancer
genet
delet
tlradaptor
protein
decreas
number
cancer
markedli
activ
turn
activ
nfkb
surpris
product
decreas
greatli
mice
defici
support
prior
data
show
one
effector
signal
activ
pathway
becker
et
al
found
suppress
tumor
progress
colon
cancer
inhibit
transsign
huntington
diseas
found
congenit
origin
diagnosi
obtain
implant
hdcrg
et
al
causal
mutat
expans
cag
trinucleotid
repeat
tract
exon
larg
gene
chromosom
result
extens
polyglutamin
tract
nterminu
encod
ubiquit
express
protein
call
huntingtin
matern
blood
dna
fetalmatern
transport
also
appli
prenat
diagnosi
bustamantearagon
et
al
hypoparathyroid
autoimmun
due
delet
syndrom
major
patient
acquir
autoimmun
antibodi
without
antiparathyroid
antibodi
lima
et
al
wegen
granulomatosi
wg
system
diseas
unknown
etiolog
character
necrot
granulomat
inflamm
tissu
necrosi
variabl
degre
vascul
small
mediums
blood
vessel
classic
clinic
pattern
triad
involv
upper
airway
lung
kidney
nineti
percent
patient
present
symptom
involv
upper
andor
lower
airway
eventu
develop
renal
diseas
mubashir
et
al
pregnanc
patient
wg
requir
preconcept
plan
care
clinic
manag
vigor
treatment
activ
diseas
manag
individu
pregnanc
outcom
variabl
antenat
manag
therapeut
option
import
koukoura
et
al
neonat
diseas
describ
ivig
treatment
could
success
appli
steroid
resist
patient
bellisai
et
al
kawasaki
diseas
kd
ill
mostli
infant
young
children
major
less
year
old
peak
age
onset
ill
month
unusu
young
infant
six
instanc
kd
occur
infant
day
age
younger
japan
infant
day
age
younger
account
patient
youngest
infant
kd
date
neonat
week
old
report
stanley
grimwood
youngest
report
india
infant
thapa
et
al
syndrom
pregnanc
also
treat
ivig
plasmapheresi
niklasson
et
al
goyal
et
al
bahadur
et
al
modi
et
al
ohlsson
laci
polyclon
antisera
administ
passiv
immun
mixtur
differ
protein
share
bind
activ
antigen
ag
determin
immunogen
prepar
immunoadhesin
immunoglobulin
fusion
protein
antibodylik
molecul
result
fusion
constant
region
eg
fc
portion
immunoglobulin
ligandbind
region
receptor
adhes
molecul
antibodi
fragment
fab
scfv
diabodi
minibodi
molecul
devoid
part
whole
fc
portion
therefor
faster
clearanc
better
tissuetumor
penetr
whole
immunoglobulin
perform
better
whole
igg
condit
short
halflif
desir
radioimag
andor
radiotherapi
adcc
cdc
trigger
activ
smallest
protein
retain
antigen
bind
singl
variabl
domain
antibodi
nieri
et
al
ivig
prevent
improv
risk
heart
block
sle
patient
friedman
et
al
sever
member
idiotypeantiidiotyp
network
antibodi
dimer
includ
antigenantibodi
complex
found
ivig
prepar
luijten
et
al
osterhau
et
al
clark
et
al
abagovomab
act
antigen
mimic
carbohydr
ovarian
cancer
antigen
wagner
et
al
frequenc
peripher
treg
increas
abagovomab
therapi
high
percentag
patient
despit
higher
treg
count
compar
baselin
level
suppress
capac
treg
reduc
subset
patient
data
indic
abil
cell
prolifer
respons
vitro
could
associ
diminish
treg
activ
importantli
immun
could
enhanc
vitro
treg
deplet
induc
treg
suppress
capac
abatacept
orencia
human
igg
fc
domain
abatacept
abt
orencia
bristolmy
squibb
ltd
rheumatoid
arthriti
tumor
necrosi
factor
inhibitor
phase
clinic
trial
found
effect
earli
phase
diseas
malottki
et
al
emeri
et
al
prophylact
withdraw
drug
pregnanc
mandatori
et
al
present
report
abatacept
tocilizumab
anakinra
inconclus
therefor
throughout
pregnanc
recommend
abciximab
reopro
chimera
plateletgp
haemostasistrombosi
nieri
et
al
use
immunohistochemistri
reopro
detect
attach
matern
fetal
platelet
trophoblast
surfac
placent
villi
miller
et
al
b
effect
abciximab
exclud
effect
monocyt
could
exclud
voisard
et
al
adalimumab
ada
humira
abbott
human
recombin
psa
cd
pp
jia
van
schouwenburg
et
al
tnfalpha
blocker
therapi
adalimumab
therapi
pregnant
show
increas
miscarriag
prematur
structur
malform
neonat
compar
nonexpos
pregnanc
et
al
express
hlag
pmbc
upregul
ankylos
spondyl
correl
acut
phase
reactant
decreas
tnfalpha
blocker
therapi
chen
et
al
use
treatment
infecti
bowel
diseas
even
pregnanc
might
influenc
develop
fetal
immun
system
arsenescu
et
al
anti
adalimumab
antiidiotyp
antibodi
barteld
et
al
malottki
et
al
nieri
et
al
direct
exposur
antitnf
treatment
pregnanc
relat
higher
incid
advers
pregnanc
outcom
infecti
bowel
diseas
overal
schnitzler
et
al
antitnf
agent
start
prior
concept
continu
evid
fetal
cardiac
activ
women
treat
combin
antitnf
therapi
anticoagul
therapi
ivig
live
birth
rate
greater
women
treat
anticoagul
therapi
alon
receiv
combin
anticoagul
therapi
ivig
fetal
outcom
includ
gestat
age
birth
weight
similar
across
group
congenit
anomali
report
antitnf
agent
exposur
winger
reed
vinet
et
al
rheumatoid
arthriti
juvenil
idiopath
arthriti
ankylos
spondyl
psoriasi
psoriat
arthriti
crohn
diseas
user
request
least
one
time
repeatedli
treatment
norway
mahic
et
al
long
term
treatment
result
reactiv
chronic
hepat
b
viru
infect
mori
treatment
caus
improv
two
bone
format
marker
phosphatas
osteocalcin
veerappan
et
al
alemtuzumab
mabcampath
genzym
human
immunoglobulin
direct
antigen
express
tand
b
lymphocyt
monocyt
macrophag
nk
cell
subpopul
granulocyt
hematolog
precursor
induct
cdc
adcc
fcreceptor
mechan
pancrea
transplant
recipi
alemtuzumab
mainten
therapi
suffer
frequent
red
cell
aplasia
autoimmun
hemolyt
anaemia
elimelakh
et
al
cordbloodhematopoeticstemcel
expans
increas
avail
cordblood
unit
transplant
lim
et
al
contrast
ivig
rituximab
compound
may
effect
therapi
complex
immunohematolog
disord
complic
hematopoiet
stem
cell
transplant
paper
emphas
import
tcell
transplant
associ
immun
cytopenia
chao
et
al
bccl
nieri
et
al
alicaforsen
human
monoclon
antibodi
also
known
leukocyt
function
antigen
lfa
ligand
intercellular
adhes
import
recruit
leukocyt
inflammatori
site
bosani
et
al
anti
intratumor
microvessel
densiti
imvd
monoclon
antibodi
effect
nonsmal
cell
lung
cancer
tanaka
et
al
mab
bristolmy
squibb
cdw
member
tumor
necrosi
factor
receptor
tnfr
superfamili
stimul
tcell
nkcell
dc
houot
et
al
mab
enhanc
rituximabdepend
cytotox
lymphoma
cell
lee
et
al
kohrt
et
al
marker
tcell
subpopul
clement
et
al
champlin
et
al
apomab
genentech
extracellular
domain
necrosi
factor
relat
trail
receptor
apoptosi
induc
ligand
nieri
et
al
basiliximab
simulect
chimer
antagonist
akta
et
al
reduc
fetal
bodi
weight
pentsuk
van
der
laan
bavituximab
peregrin
pharmaceut
inc
tustin
ca
antiphosphatidylserin
bavituximab
combin
radiotherapi
hold
promis
vascular
target
immun
enhanc
strategi
treatment
human
glioblastoma
et
al
hcv
therapi
immunostimul
dammacco
et
al
quer
et
al
belatacept
new
recombin
molecul
interfer
signal
lymphocyt
activ
prevent
acut
reject
renal
transplant
hlag
act
natur
tolerogen
molecul
human
patient
treat
display
significantli
higher
solubl
hlag
shlag
plasma
concentr
patient
treat
calcineurin
inhibitor
healthi
donor
bahri
et
al
dc
act
tolerogen
apc
shlag
secret
suppress
cell
alloprolifer
could
restor
use
neutral
antihlag
ab
bahri
et
al
use
anti
tumour
necrosi
factor
mab
recommend
partlett
roussou
cytotox
tlymphocyteassoci
protein
neg
regul
cell
activ
may
modul
peripher
selftoler
kaufman
et
al
bevacizumab
avastin
human
antivascular
endotheli
growth
factora
vegfa
use
treatment
nonsmal
cell
lung
cancer
nsclc
colorect
cancer
cc
nieri
et
al
efd
rabbit
dosedepend
decreas
matern
bodyweight
increas
fetal
malform
late
resorpt
pentsuk
van
der
laan
intravitr
bevacizumab
therapi
pregnanc
offlabel
ocular
indic
result
signific
visual
improv
without
advers
fetal
event
relat
treatment
tarantola
et
al
intravitr
mg
bevacizumab
may
reach
system
circul
plasma
concentr
ngml
two
pregnant
lost
babi
within
day
follow
intravitr
inject
bevacizumab
petrou
et
al
placenta
gf
level
elev
plasma
colorect
rectal
carcinoma
patient
receiv
bevacizumab
xu
jain
prevent
angiogenesi
msc
pancreat
cancer
beckermann
et
al
blinatumomab
epcam
antigen
epitheli
celladhes
molecul
present
cancer
cell
present
nonhodgin
lymphoma
cell
armstrong
eck
nieri
et
al
bispecif
singl
chain
recombin
antibodi
houot
et
al
topp
et
al
catomaxomab
removab
bifunct
recombin
anti
epiderm
cell
adhes
molecul
epcam
induc
adcc
ovarian
stomach
cancer
epcam
ligand
human
leukocyt
immuneglobulin
like
receptor
armstrong
eck
nieri
et
al
bokemey
et
al
ceavac
mimick
carcinoembryon
antigen
colon
cc
foon
et
al
certolizumab
ucb
pegyl
human
antibodi
fab
fragment
monoclon
antibodi
ra
cd
certolizumab
cross
placenta
easili
igg
deriv
drug
due
pegyl
molecul
thu
reduc
harm
consequ
fetu
clows
cetuximab
erbitux
chimer
antiepiderm
growth
factor
apoptosi
cdcc
colorect
cancer
cc
squamou
cell
cancer
head
neck
scchn
weight
loss
reduc
food
consumpt
highdos
group
dosedepend
increas
abort
rate
known
could
associ
treatment
weight
loss
reduc
food
consumpt
highdos
group
powel
et
al
pentsuk
van
der
laan
rech
vonderheid
human
antibodi
aglycosyl
human
antibodi
direct
shown
reduc
insulinrequir
patient
residu
betacel
function
better
maintain
placebo
keymeulen
et
al
cixutumumab
cix
target
insulinlik
growth
factor
receptor
igfir
treatment
multipl
cancer
human
block
interact
igfir
ligand
igfi
ii
induc
intern
degrad
igfir
combin
cetuximab
mab
egfr
inhibit
growth
pancreat
cancer
promot
regress
antiangiogen
mechan
associ
cix
treatment
review
recent
quatral
et
al
hyperglycemia
regular
side
effect
fetal
consequ
pregnanc
evalu
yet
mckian
haluska
eyelash
trichomegali
adult
et
al
garrido
et
al
cnto
chimer
monoclon
antibodi
high
affin
human
myeloma
multiplex
sensit
glycocorticoid
voorhe
et
al
curetech
human
mab
bind
mous
human
program
death
receptor
blockag
abrog
protect
effect
regulatori
cell
pregnanc
murin
model
houot
et
al
mkrtichyan
et
al
stagg
et
al
wafula
et
al
dacetuzumab
seattl
genet
human
fulli
human
novartisxoma
tumour
necrosi
factor
receptor
bcell
dc
macrophag
lymphoma
houot
et
al
daclizumab
zenapax
human
antagonist
elimelakh
et
al
akta
et
al
transplant
reject
eculizumab
soliri
human
antihuman
complement
paroxism
nocturn
haemoglobinuria
pnh
thoma
et
al
nieri
et
al
danilov
et
al
evid
complement
blockad
cord
blood
sampl
taken
deliveri
eculizumab
appear
safe
use
set
like
prevent
mani
complic
usual
observ
kelli
et
al
edrecolomab
panorex
epcam
antigen
cdcadcc
cancer
nieri
et
al
efalizumab
raptiva
human
psoriasi
nieri
et
al
progress
multifoc
leukoencephalopthi
found
rare
lethal
diseas
associ
long
term
efalizumab
therapi
kothari
et
al
epratuzumab
human
unconjug
antibodi
effect
nonhodgkin
lymphoma
follicular
lymphoma
leonard
et
al
watanab
consequ
applic
pregnanc
report
etanercept
etn
enbrel
wyeth
pharmaceut
human
igg
fc
domain
psa
pp
jia
ngml
cord
blood
ngml
week
postpartum
ngml
week
postpartum
undetect
week
postpartum
clows
reduct
postpartum
microchimer
rak
et
al
complic
therapi
may
acut
anterior
uveiti
etanercept
psoriasi
infliximab
etanercept
infecti
bowel
diseas
ibd
etanercept
infliximab
observ
associ
treatment
use
tnfantagonist
paradox
consequ
howev
affect
less
treat
patient
fouach
et
al
eternacept
recombin
human
solubl
receptor
tnf
fail
phase
ii
trial
crohn
diseas
trial
discontinu
recombin
receptor
prove
use
treatment
rheumatoid
arthriti
malottki
et
al
use
pregnant
approv
et
al
etanercept
treatment
mg
stop
week
pregnanc
treatment
reiniti
week
pregnanc
fetal
complic
observ
umeda
et
al
etanercept
treatment
initi
week
pregnanc
mgsqm
weekli
cord
blood
contain
ngml
etanercept
contrast
matern
serum
ngml
detect
etanercept
found
newborn
blood
week
deliveri
although
breast
milk
contain
ngml
etanercept
murashima
et
al
patient
request
least
one
time
repetit
treatment
accord
public
norway
mahic
et
al
fontolizumab
use
prevent
treatment
newborn
risk
respiratori
syncyti
viru
infect
rsv
result
signific
decreas
creactiv
protein
level
suggest
benefici
biolog
effect
nieri
et
al
reinisch
et
al
galiximab
humanprim
chimer
antibodi
galiximab
humanprim
chimer
antibodi
excel
toler
singleag
effect
recurr
follicular
lymphoma
fl
resist
therapeut
mean
watanab
gemtuzumab
humanis
myeloid
cell
drug
target
nieri
et
al
golimumab
centocor
ortho
biotech
human
monoclon
antibodi
ra
psa
novartisxoma
fulli
human
mab
antagonist
activ
mediat
adcc
block
surviv
prolifer
normal
malign
b
cell
chatenoud
blueston
ibritumomab
tiuxetan
zevalin
murin
radiol
yttrium
nieri
et
al
infliximab
ifx
remicad
scheringplough
ltd
chimer
antitumor
necrosi
factor
alpha
rheumatoid
arthriti
ra
crohn
diseas
cd
saleem
et
al
van
schouwenburg
et
al
fatal
case
dissemin
mycobacteri
infect
report
infant
receiv
bcg
vaccin
month
age
mother
treat
infliximab
throughout
pregnanc
vaccin
live
bacteria
virus
postpon
infant
expos
infliximab
utero
serum
level
undetect
may
requir
month
djokanov
et
al
fetal
concentr
infliximab
found
higher
mother
might
risk
postnat
develop
immun
system
zelinkova
et
al
due
high
rate
igg
transfer
near
term
babi
found
similar
blood
level
infliximab
mother
clows
report
pregnanc
outcom
treatment
infliximab
show
increas
miscarriag
prematur
structur
malform
neonat
compar
nonexpos
pregnanc
et
al
chimer
monoclon
antitnf
antibodi
infliximab
current
avail
worldwid
potenc
agent
moderatetosever
ulcer
coliti
uc
cd
one
import
advanc
care
inflammatori
bowel
diseas
ibd
past
decad
haen
daperno
antiinfliximab
antiidiotyp
associ
found
patient
allotyp
presenc
concentr
antiinfliximab
antibodi
barteld
et
al
reduct
fertil
known
whether
relat
male
femal
anim
pentsuk
van
der
laan
vacterl
associ
acut
graft
versu
host
diseas
couriel
et
al
describ
prove
use
treatment
rheumatoid
arthriti
malottki
et
al
inotuzumab
ozogamicin
calicheamicinconjug
monoclon
antibodi
rituximab
combin
use
treatment
ankylos
spondil
psoriat
arthriti
ulcer
coliti
nieri
et
al
smith
et
al
concentr
blood
newborn
week
postpartum
slowli
declin
month
clows
ipilimumab
bind
overcom
immunosuppress
increas
anticanc
immunerespons
melanoma
malignum
bristolmy
squibbmedarex
cell
treg
cell
colon
prostat
cancer
nieri
et
al
houot
et
al
iratumumab
igg
use
treatment
hodgkin
lymphoma
myelosuppress
fatigu
elev
liver
enzym
document
therapi
klimm
et
al
fulli
human
antirhesu
rhd
antibodi
prevent
fetomatern
alloimmun
rhd
women
substitut
human
polyclon
antirhd
immunoglobulin
urbain
et
al
monoclon
antibodi
direct
treatment
b
cell
malign
antibodydepend
cellular
cytotox
adcc
activ
enhanc
affin
fcgriii
correl
glycosyl
pattern
character
low
fucos
content
urbain
et
al
mapatumumab
trail
receptor
activ
death
receptor
mediat
apoptosi
cancer
cell
nieri
et
al
matuzumab
humanis
antiegfr
monoclon
antibodi
review
seiden
et
al
recent
quatral
et
al
melimmun
antiidiotyp
antibodi
mimic
high
molecular
weight
chondroitin
sulfat
proteoglycan
antigen
melanoma
cell
pride
et
al
murray
et
al
ward
et
al
mitumomab
imclon
system
antiidiotyp
giaccon
et
al
bottomley
et
al
antiidiotyp
antibodi
mimic
gangliosid
express
surfac
tumor
cell
neuroectoderm
origin
gangliosid
use
vaccin
small
cell
lung
cancer
sclc
nieri
et
al
integrin
antibodi
type
humanis
review
bosani
et
al
approv
treatment
crohn
diseas
motavizumab
humanis
mous
monoclon
antibodi
motavizumab
target
highli
conserv
epitop
antigen
site
rsv
fusion
f
protein
import
invas
rsv
cell
cell
motavizumab
differ
palivizumab
amino
acid
exhibit
enhanc
bind
rsv
f
protein
compar
firstgener
mab
faster
associ
rate
sixfold
slower
disassoci
rate
nieri
et
al
weisman
muromonab
murin
tcell
blocad
monoclon
antibodi
reestablish
immun
homeostasi
treat
individu
occur
modul
tcell
receptor
tcr
complex
also
term
antigen
modul
andor
induct
apoptosi
activ
autoreact
cell
leav
behind
space
homeostat
reconstitut
favour
select
induct
surviv
expans
adapt
regulatori
cell
establish
longterm
toler
use
earli
treatment
diabet
type
chatenoud
blueston
nieri
et
al
natalizumab
tysabri
human
treatment
sclerosi
multiplex
van
schouwenburg
et
al
natalizumab
block
integrin
vcam
integrin
madcam
interact
rutgeert
et
al
therapi
sclerosi
multiplex
effici
combin
interferon
miller
et
al
b
nieri
et
al
anim
experi
efd
g
pig
reduc
pregnanc
rate
highdos
group
ppnd
cyn
increas
abort
stillbirth
rate
pentsuk
van
der
laan
cynomolgu
monkey
howev
abort
rate
increas
hematopoet
chang
observ
natalizumab
advers
effect
gener
health
surviv
develop
immunolog
structur
function
infant
born
dam
treat
natalizumab
pregnanc
wehner
et
al
b
natalizumab
therapi
stop
pregnanc
three
patient
treat
least
month
develop
progress
multifoc
encephalopathi
pml
piehl
et
al
pml
induct
document
natalizumab
therapi
crohn
diseas
first
kleinschmidtdemast
tyler
sandborn
et
al
van
assch
et
al
edula
picco
necitumumab
antiegfr
human
monoclon
antibodi
kuenen
et
al
nimotuzumab
theracim
humanis
apoptosi
adcc
head
neck
cancer
hncc
spicer
nieri
et
al
review
recent
quatral
et
al
omalizumab
xolair
human
antiig
asthma
caus
mark
reduct
serum
level
free
ige
downregul
ige
receptor
circul
basophil
effect
monozygot
twin
holgat
et
al
et
al
nieri
et
al
toler
corren
et
al
onercept
recombin
human
solubl
receptor
tnf
fail
phase
ii
trial
crohn
diseas
trial
discontinu
bosani
et
al
palivizumab
synagi
human
antirespiratori
syncyti
viru
epitop
fusion
protein
use
prevent
respiratori
syncyti
viru
infect
newborn
differ
risk
respiratori
infect
martinmateo
nieri
et
al
weisman
panitumumab
vectibix
human
antihuman
epiderm
growth
factor
receptor
bind
catalyt
kinas
domain
receptor
colorect
cancer
cc
nieri
et
al
increas
frequenc
abortionfet
death
rate
observ
highdos
group
review
pentsuk
van
der
laan
nieri
et
al
eyelash
trichomegali
adult
seen
zhang
et
al
morri
et
al
racotumomab
antiidiotyp
vaccin
mimick
gangliosid
guthmann
et
al
et
al
effect
breast
lung
cancer
practic
undetect
healthi
human
tissu
result
alumedi
inactiv
gene
gangliosid
highli
express
sever
human
cancer
cell
presum
due
incorpor
dietari
ngc
fernandez
et
al
ramucirumab
antibodi
vegf
tonra
et
al
krupitskaya
wakele
ranibizumab
lucenti
genentech
human
antihuman
vasc
endothel
growth
factora
vegfa
treatment
choroid
neovascular
wet
agerel
macular
degener
armd
review
recent
ferrara
et
al
neovascular
acut
myeloid
leukemia
neovascularaml
nieri
et
al
retuximab
epsteinbarr
viru
sodani
et
al
rituximab
rtx
roch
chimer
sulesomab
leukoscan
murin
fab
bind
surfac
granulocyt
nonspecif
crossreact
antigen
present
neutrophil
rhiniti
fever
chill
toxic
laboratori
find
occur
treatment
klimm
et
al
hcv
cryoglobulinaemia
could
also
treat
dammacco
et
al
treatment
pregnant
bukitt
lymphoma
result
high
rituximab
concentr
transient
complet
bcell
deplet
cord
blood
bcell
recoveri
fast
show
regular
immunophenotyp
without
loss
antigen
function
deficit
adequ
vaccin
igg
titer
friedrich
et
al
administr
third
trimest
pregnanc
suppress
neonat
bcell
develop
without
later
neonat
consequ
klink
et
al
spite
prophylact
withdraw
recommend
pregnanc
et
al
human
fetal
bcell
deplet
lymphocytopenia
cynomolgu
observ
vaidyanathan
et
al
reduct
postpartum
microchimer
document
rak
et
al
use
rheumatoid
arthriti
therapi
malottki
et
al
combin
chemotherapi
depend
human
concentr
nucleotid
transport
gene
express
rate
rabascio
et
al
nonhodgkin
lymphoma
rheumatoid
arthriti
indic
nieri
et
al
costimulatori
molecul
express
varieti
immun
cell
activ
includ
nk
cell
stimul
specif
igg
enhanc
antilymphoma
activ
antibodi
enhanc
adcc
kohrt
et
al
pregnanc
known
outcom
result
live
birth
twentytwo
infant
born
prematur
one
neonat
death
week
eleven
neonat
hematolog
abnorm
none
correspond
infect
four
neonat
infect
report
fever
bronchiol
cytomegaloviru
hepat
chorioamnion
two
congenit
malform
identifi
clubfoot
one
twin
cardiac
malform
singleton
birth
one
matern
death
preexist
autoimmun
thrombocytopenia
occur
women
continu
counsel
avoid
pregnanc
month
rituximab
exposur
howev
inadvert
pregnanc
occasion
occur
practition
encourag
report
complet
inform
regulatori
author
pregnanc
suspect
known
exposur
rituximab
chakravarti
et
al
due
ongo
bleed
rituximab
given
week
pregnanc
platelet
count
rose
l
week
neonat
blymphocyt
count
normal
month
deliveri
neonat
complic
rituximab
therapi
gall
et
al
passeng
lymphocyt
syndrom
describ
lee
et
al
b
siplizumab
humanis
igglk
monoclon
antibodi
bind
human
antigen
preclin
studi
demonstr
siplizumab
kill
target
cell
adcc
fanal
youn
watanab
teplizumab
human
fc
mutat
monoclon
antibodi
induc
toler
progress
type
diabet
patient
recentonset
diseas
even
year
first
diagnosi
herold
et
al
tocilizumab
toc
roactemra
roch
receptor
mous
antibodi
human
chain
creat
human
antibodi
human
bind
site
low
concentr
microgml
tocilizumab
antihuman
receptor
monoclon
antibodi
inhibit
matrixmetalloproteinas
mmp
secret
shown
stimul
preterm
prematur
ruptur
membran
pprm
sato
et
al
mano
et
al
malottki
et
al
pham
et
al
clinic
phase
trial
treatment
rheumatoid
arthriti
approv
inherit
autoinflammatori
syndrom
sometim
treat
anakinra
tocilizumab
goldfing
present
report
abatacept
tocilizumab
anakinra
inconclus
therefor
throughout
pregnanc
recommend
normal
pregnanc
characteris
elev
activ
antiinflammatori
cytokin
first
trimest
follow
increas
activ
proinflammatori
factor
near
term
challi
et
al
contrast
preeclampsia
pe
mark
increas
proinflammatori
tumor
necrosi
interleukin
cytokin
well
decreas
antiinflammatori
cytokin
case
restrict
fetal
growth
also
elev
compar
normal
pregnanc
et
al
women
live
versu
colorado
higher
proinflammatori
rel
antiinflammatori
cytokin
second
third
trimest
coussonsread
et
al
multigener
andean
versu
shorter
durat
european
highaltitud
resid
found
protect
altitudeassoci
fetal
growth
restrict
higher
might
play
role
protect
altitudeassoci
reduct
fetal
growth
coussonsread
et
al
et
al
tocilizumab
treatment
increas
serum
level
solubl
nishimoto
et
al
combin
drug
adult
onset
still
diseas
improv
use
monoclon
antibodi
efthimi
georgi
tositumomab
igg
bcell
lymphoma
armstrong
eck
nieri
et
al
trastuzumab
herceptin
human
induct
cdc
adcc
fcreceptor
mechan
human
anhydramnion
oligohydramnion
develop
caus
fetal
kidney
insuffici
watson
robinson
et
al
katsumi
et
al
matsumoto
et
al
decreas
amniot
fluid
seem
revers
discontinu
trastuzumab
sukumvanich
transfer
use
aavrecombin
mice
induc
antiidiotyp
wang
et
al
b
mechan
toxic
fetal
kidney
propos
associ
differ
structur
egfr
fetal
renaltubul
epitheli
cell
heterodim
egfr
fetu
vs
homodim
egfr
adult
thu
trastuzumab
damag
effect
fetal
renal
function
affect
kidney
adult
robinson
et
al
antitrastuzumab
ladjemi
et
al
antitrastuzumab
antiid
use
therapeut
prophylact
vaccin
protect
mice
develop
mammari
tumor
induc
antibodi
product
immun
respons
result
suggest
could
use
antiidbas
vaccin
adjuv
therapi
patient
tumor
revers
immunolog
toler
calmodulin
inhibitor
rescu
trastuzumab
sensit
breast
tumour
kulkarni
et
al
major
patient
abl
toler
therapi
howev
oligohydramnio
anhydramnio
occur
patient
decreas
amniot
fluid
seem
revers
discontinu
trastuzumab
sukumvanich
tremelimumab
pfizer
cell
treg
cell
colon
prostat
cancer
houot
et
al
triab
triab
breast
cancer
reec
et
al
trigerm
disialogangliosid
melanoma
foon
et
al
tositumomab
iodin
label
murin
cdc
adcc
radiocytotox
nonhodgkinlymphoma
nieri
et
al
veltuzumab
human
antibodi
structurefunct
differ
chimer
rituximab
watanab
visilizumab
manag
crohn
diseas
cd
ulcer
coliti
uc
biolog
evalu
approv
uc
discuss
includ
monoclon
antibodi
tumor
necrosi
factor
tnf
infliximab
inhibitor
adhes
molecul
alicaforsen
antibodi
visilizumab
antiinterleukin
il
receptor
antibodi
daclizumab
biolog
evalu
approv
cd
review
includ
three
monoclon
antibodi
tnf
infliximab
adalimumab
certolizumab
pegol
monoclon
antibodi
receptor
inhibitor
adhes
molecul
natalizumab
alicaforsen
growth
factor
chimer
monoclon
antitnf
antibodi
infliximab
current
avail
worldwid
haen
daperno
yttriumibritumomab
tiuxetan
iodinerituximab
monoclon
antibodi
combin
radioact
materi
diagnost
andor
therapeut
applic
watanab
zalutumumab
antiegfr
mab
abl
facilit
complement
lysi
cancer
cell
klausz
et
al
review
recent
quatral
et
al
cytotox
lymphocyt
program
cell
death
member
known
tregassoci
molecul
block
abrog
protect
effect
treg
result
higher
median
abort
rate
comparison
treg
isotypetr
control
blockag
interfer
protect
effect
treg
import
mediat
treginduc
fetal
protect
cba
j
dba
murin
model
wafula
et
al
shown
interact
result
termin
immun
respons
alegr
et
al
mice
genet
defici
express
develop
lymphoprolif
diseas
termin
death
week
age
tivol
et
al
waterhous
et
al
possess
also
role
regul
tcell
sansom
walker
blockad
interact
ligand
shown
induc
antigenspecif
peripher
toler
organ
transplant
knowledg
success
use
anim
model
prevent
allograft
reject
block
andor
therebi
lead
longterm
graft
surviv
cytokin
favor
mainten
fetal
surviv
mainli
belong
eg
wherea
pregnanc
failur
associ
cytokin
eg
maternofet
interfac
andor
absenc
cytokin
combin
use
mab
mice
effect
induc
matern
toler
allogen
fetu
blockad
vivo
costimul
could
prevent
abort
shift
cytokin
predomin
bia
expand
peripher
regulatori
cell
jin
et
al
breakdown
immunolog
self
toler
maintain
activ
cell
express
receptor
result
develop
autoimmun
diseas
sakaguchi
et
al
sakaguchi
mitig
use
monoclon
suppress
treg
cell
elev
also
pregnanc
somerset
et
al
intergin
progress
multifoc
leukoencephalopathi
observ
pml
probabl
polyomaviru
etiolog
natalizumab
therapi
crohn
diseas
edula
picco
tnfalpha
blocker
shown
induc
autoimmun
ana
antidsdna
antibodi
ra
spa
patient
autoimmun
induc
frequent
infliximab
etanercept
lesser
degre
adalimumab
therapi
importantli
emerg
autoimmun
except
associ
clinic
manifest
lupu
bacquetdeschryv
et
al
effect
infliximab
etanercept
adalimumab
spermatogenesi
studi
patient
spondylarthr
villig
et
al
sperm
abnorm
found
healthi
control
patient
antitnf
therapi
show
significantli
better
sperm
motil
vital
untreat
patient
antibodi
product
licens
prevent
treatment
viral
diseas
includ
nonimmun
human
immunoglobulin
use
hepat
measl
virusspecif
polyclon
human
immunoglobulin
cytomegaloviru
hepat
b
rabi
respiratori
syncyti
viru
rsv
vaccinia
varicellazost
human
monoclon
antibodi
palivizumab
fonolizumab
motavizumab
groothui
et
al
polyclon
immunoglobulin
also
use
variou
success
diseas
caus
human
virus
includ
parvoviru
pv
lassa
viru
west
nile
viru
enterovirus
herp
simplex
viru
crimeancongo
haemorrhag
fever
viru
cchfv
junin
viru
sever
acut
respiratori
syndromeassoci
coronaviru
sar
cov
human
immunodefici
viru
hiv
serum
polyclon
antibodi
prepar
clinic
effect
mani
case
problem
relat
toxic
includ
risk
allerg
reaction
lot
lot
variat
uncertain
dose
limit
use
casadeval
use
rabi
tickborn
enceph
virusspecif
hyperimmun
gamma
globulin
use
sever
countri
immedi
follow
viru
exposur
anim
injuri
tick
bite
cytomegalovirusspecif
hyperimmun
gamma
globulin
use
transplant
surgeri
schmitz
essuman
era
gancyclovir
prevent
therapi
sar
cov
surfac
glycoprotein
also
call
spike
glycoprotein
protein
glycoprotein
mediat
viral
entri
host
cell
two
function
domain
domain
involv
bind
cellular
receptor
wherea
domain
facilit
fusion
viral
host
cell
membran
infect
mani
virus
includ
coronavirus
elicit
potent
neutral
antibodi
nab
affect
cours
infect
help
clear
viru
also
protect
uninfect
host
expos
viru
improv
method
epsteinbarr
viru
ebv
transform
human
b
cell
develop
base
cpg
oligonucleotid
increas
b
cell
immort
effici
method
use
select
human
ab
specif
sar
cov
protein
one
select
antibodi
specif
glycoprotein
viral
spike
effici
neutral
convalesc
serum
nipah
viru
niv
hendra
viru
hev
close
relat
emerg
paramyxovirus
compris
henipaviru
genu
biolog
safeti
pathogen
niaid
biodefens
research
agenda
zoonot
emerg
categori
c
prioriti
pathogen
could
use
bioterror
agent
zhu
et
al
monoclon
antibodi
enzym
activ
develop
use
cancer
therapi
applic
treatment
pregnant
women
present
yet
approv
kulkarni
et
al
quatral
et
al
immunotherapi
offer
rang
potenti
treatment
option
drug
treatment
well
treatment
overdos
prevent
brain
cardiac
toxic
fetal
protect
pregnant
drug
abus
clinic
trial
cocain
nicotin
vaccin
shown
induc
antibodi
titer
produc
side
effect
haney
kosten
plasmin
may
serv
major
drive
autoantigen
anticardiolipin
acl
antiphospholipid
syndrom
ap
patient
posit
igg
antiplasmin
ab
one
mab
display
anticardiolipin
acl
lupu
anticoagul
lac
activ
induc
fetal
loss
inject
pregnant
mice
chen
et
al
molecular
mimicri
suggest
play
role
pathogenesi
mani
autoimmun
diseas
allerg
encephalomyel
experiment
myocard
experiment
autoimmun
kerat
uveiti
antigen
molecular
mimicri
characteris
antidna
antibodi
react
differ
protein
ie
enzym
blank
shoenfeld
case
schizophrenia
overal
find
monozygot
twin
seriou
neuroment
disord
nmd
ident
twin
risk
wherea
among
dizygot
twin
risk
one
afflict
neuroment
disord
nmd
might
caus
indirectli
matern
transplacentallyacquir
antibodi
agent
epitop
molecular
mimicri
develop
nervou
system
caus
alter
clinic
manifest
year
later
nahmia
et
al
serolog
evid
previou
exposur
ebv
children
ms
support
role
ebv
infect
earli
ms
pathogenesi
alreadi
indic
prospect
studi
adult
higher
antibodi
titer
tcell
respons
ebv
patient
compar
healthi
ebv
carrier
indic
possibl
continu
viral
reactiv
ms
patient
increas
tcell
respons
ebv
antigen
particularli
evid
ebv
could
break
immun
toler
myelin
antigen
molecular
mimicri
detect
ebvinfect
bcell
patient
brain
rais
possibl
intrathec
bcell
abnorm
tcellmedi
immunopatholog
ms
consequ
persist
dysregul
ebv
infect
accordingli
target
tcell
andor
bcell
monoclon
antibodi
therapi
amelior
ms
whether
ebv
caus
pathogen
role
ms
address
relat
genet
hormon
environment
influenc
may
affect
interact
salvetti
et
al
function
suppress
regulatori
cell
also
found
impair
ms
patient
viglietta
et
al
newborn
pregnant
suffer
multipl
sclerosi
ms
impair
diseas
case
father
newborn
suffer
ms
neg
consequ
could
documentet
ie
safe
patern
characteris
mspatient
result
mother
seem
impact
birth
weight
howev
ms
may
contribut
reduc
birth
weight
hellwig
et
al
mother
suffer
ms
usual
treat
longterm
interferon
ifn
betatherapi
spite
pregnanc
foetal
exposur
subcutan
interferon
therapi
treatment
discontinu
least
day
pregnanc
expos
day
rate
spontan
abort
major
congenit
anomali
live
birth
line
observ
gener
popul
amato
et
al
sandbergwollheim
et
al
vitro
suscept
bewo
cell
increas
toxoplasma
gondii
follow
treatment
interferon
gamma
interleukin
transform
growth
factor
barbosa
et
al
similar
consequ
observ
pregnanc
vivo
